{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:30Z","timestamp":1789001250412,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cannabinoid-based therapies are increasingly used in cancer care to manage symptoms such as pain, chemotherapy-induced nausea and distress in palliative settings. Despite their clinical adoption, the safety profiles of these therapies remain incomplete. This systematic review synthesises randomised controlled trials (RCTs) reporting adverse events (AEs) associated with cannabinoid-based therapies in adult patients with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, CINAHL and Web of Science for studies published between January 2015 and March 2025. Eligible studies included RCTs involving adult patients with cancer receiving cannabinoid-based treatments that reported AEs. Data were extracted on study characteristics, intervention type and AEs, which were categorised by systemic disorder. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines were followed throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14 RCTs were included. Studies varied in sample size (12 to 399), intervention duration (48 hours to 12 months), and cannabinoid formulations. All studies reported AEs, with the most frequent involving gastrointestinal (eg, nausea, dry mouth), neurological (eg, dizziness, somnolence) and psychiatric (eg, anxiety, hallucinations) disorders. The number of distinct AEs reported per study ranged from 1 to more than 12. Risk of bias assessments revealed that 10 studies had \u2018some concerns\u2019 and 2 were classified as \u2018high risk\u2019 due to incomplete outcome reporting or selective bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cannabinoid therapies are associated with a broad range of AEs in adult patients with cancer, particularly affecting the gastrointestinal and nervous systems. While these therapies may offer symptomatic relief, clinicians must weigh benefits against potential harms. Further studies with larger samples, longer follow-ups and standardised AE reporting are recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2025-005759","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:00:16Z","timestamp":1762848016000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events and cannabinoid use in cancer management: systematic review"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2080-8204","authenticated-orcid":false,"given":"Tumen","family":"Sosorburam","sequence":"first","affiliation":[{"name":"Department of Health Administration and Policy, College of Public Health, George Mason University, Fairfax, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2026041707351394000_16.1.20.1","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"key":"2026041707351394000_16.1.20.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1221"},{"key":"2026041707351394000_16.1.20.3","unstructured":"Sciences N . The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017."},{"key":"2026041707351394000_16.1.20.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1470919"},{"key":"2026041707351394000_16.1.20.5","doi-asserted-by":"publisher","DOI":"10.1016\/0952-3278(95)90077-2"},{"key":"2026041707351394000_16.1.20.6","first-page":"S163","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147 Suppl 1","author":"Pertwee","year":"2006","journal-title":"Br J Pharmacol"},{"key":"2026041707351394000_16.1.20.7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.46.120604.141254"},{"key":"2026041707351394000_16.1.20.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6358"},{"key":"2026041707351394000_16.1.20.9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.108","article-title":"Cannabis in cancer care","volume":"97","author":"Abrams","year":"2015","journal-title":"Clin Pharma and Therapeutics"},{"key":"2026041707351394000_16.1.20.10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1818","article-title":"Medical Cannabinoids in Children and Adolescents: A Systematic Review","volume":"140","author":"Wong","year":"2017","journal-title":"Pediatrics"},{"key":"2026041707351394000_16.1.20.11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(09)61037-0","article-title":"Adverse health effects of non-medical cannabis use","volume":"374","author":"Hall","year":"2009","journal-title":"The Lancet"},{"key":"2026041707351394000_16.1.20.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.08.026"},{"key":"2026041707351394000_16.1.20.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.09.001"},{"key":"2026041707351394000_16.1.20.14","doi-asserted-by":"publisher","DOI":"10.1177\/2049463717710042"},{"key":"2026041707351394000_16.1.20.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026041707351394000_16.1.20.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50391","article-title":"Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial","volume":"7","author":"Nayak","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026041707351394000_16.1.20.17","first-page":"3029","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"2026041707351394000_16.1.20.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06301-x"},{"key":"2026041707351394000_16.1.20.19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/jpm.2019.0540","article-title":"An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care","volume":"23","author":"Good","year":"2020","journal-title":"J Palliat Med"},{"key":"2026041707351394000_16.1.20.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-08091-z","article-title":"Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC\/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial","volume":"25","author":"Gurgenci","year":"2024","journal-title":"Trials"},{"key":"2026041707351394000_16.1.20.21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649555","article-title":"A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas","volume":"11","author":"Schloss","year":"2021","journal-title":"Front Oncol"},{"key":"2026041707351394000_16.1.20.22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41416-021-01259-3","article-title":"A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma","volume":"124","author":"Twelves","year":"2021","journal-title":"Br J Cancer"},{"key":"2026041707351394000_16.1.20.23","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.22.01632","article-title":"Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)","volume":"41","author":"Hardy","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041707351394000_16.1.20.24","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.23.01836","article-title":"Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II\/III Trial","volume":"42","author":"Grimison","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041707351394000_16.1.20.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01880-2"},{"key":"2026041707351394000_16.1.20.26","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.eujim.2023.102279","article-title":"Adverse events associated with the use of cannabis-based products in people living with cancer: A scoping review protocol","volume":"62","author":"Cheah","year":"2023","journal-title":"Eur J Integr Med"},{"key":"2026041707351394000_16.1.20.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.06.008"},{"key":"2026041707351394000_16.1.20.28","doi-asserted-by":"publisher","DOI":"10.1177\/0003489415612801"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:36:55Z","timestamp":1776436615000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/spcare-2025-005759"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005759","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}